Three Innovative Drugs from Leads Biolabs will be Reported at the 2024 CSCO Annual Meeting

The 2024 Chinese Society of Clinical Oncology（CSCO）Annual Meeting will be held in Xiamen from September 25^th to September 29^th. As the most authoritative and influential annual event in the field of oncology in China, CSCO consistently propels the advancement and development of oncology disciplines in China and even the world with forward-looking topic selection, high-level academic exchanges, and strict review mechanisms. It is an important benchmark for evaluating innovative achievements in oncology research. Three clinical-stage innovative drugs from Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) have successfully been selected to be reported in 2024 CSCO Annual Meeting, with two of them standing out as oral presentations in the Innovation Session.

LBL-024 is a tetravalent bispecific antibody that simultaneously targets PD-L1 and 4-1BB, serving dual functions: blocking the immunosuppressive PD-1/PD-L1 pathway, and selectively co-stimulating 4-1BB in the tumor microenvironment to enhance immune responses. The dual functions of LBL-024—lifting PD-1/PD-L1 immune inhibition and intensifying 4-1BB modulated T cell activation—synergistically enhance the anti-tumor immune response.

At the CSCO annual meeting, safety and efficacy data of LBL-024 as monotherapy in patients with advanced malignancies, particularly in extrapulmonary neuroendocrine carcinomas (EP-NEC), will be presented, showcasing its exceptional safety and effectiveness.

LBL-007 is a fully human IgG4 monoclonal antibody targeting LAG3. LBL-007 is designed with a unique structure that allows it to bind to specific epitope of LAG3 with high affinity and block LAG3's interaction with all four identified ligands. Upon binding to LAG3, LBL-007 induces potent endocytosis, thereby modulating intracellular signaling pathways independently of ligand interaction and enhancing immune responses.

At the CSCO Annual Meeting, safety and efficacy data of LBL-007 combined with tislelizumab and chemotherapy in previously untreated patients with advanced nasopharyngeal carcinoma will be reported, demonstrating clinical manageable safety profile and encouraging anti-tumor efficacy.

LBL-007, as one of the pioneering LAG-3 antibodies, has exhibited robust efficacy in melanoma and other specific cancer types and is currently being evaluated under Phase II clinical trials mainly for the treatment of five cancer indications in China and worldwide.

LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3, is the third GPRC5D-targeted CD3 T-cell engager to enter clinical stage in the world, according to Frost & Sullivan. LBL-034 selectively binds to T cells only in the presence of GPRC5D+ cells, thereby conditionally activating T cells in the tumor microenvironment where GPRC5D is expressed.

The poster will showcase preliminary clinical data from the I/II study of LBL-034 as monotherapy in relapsed/refractory multiple myeloma (RRMM), demonstrating the manageable safety and good anti-tumor activity.

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said,” Since its establishment, Leads Biolabs has steadfastly adhered to the corporate philosophy of 'Care for Life, Focus on Innovation and Win-Win Cooperation'. We have consistently bolstered our R&D investments, assembled a team of top scientific research talents from both domestic and international arenas, and cultivated an open and collaborative innovation ecosystem, with the aspiration of becoming a global leader in therapeutic antibody drug development. The inclusion of clinical research data for our three innovative drug candidates at the CSCO Annual Meeting is not only a high recognition of Leads Biolabs' robust research and development capabilities but also an affirmation of the company’s unwavering dedication to an innovation-driven development strategy.”